Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
Key Points
Key Points
- The focus of this guideline is advanced or metastatic well-differentiated G1-G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors arising in sites such as the pancreas, stomach, small intestine, colon, rectum, and appendix.
- These are classified according to mitotic rate or Ki-67 index (a measure of the percentage of primary tumor cells that are dividing).
- This guideline focuses on strategies for controlling the growth of these tumors.
Treatment
...I. General...
....1Selection of initial treatment opt...
...ecommendation 1.2All treatment decisions should...
...1.3Patients should be assessed for SSTR p...
...II. Systemic Therap...
...First-li...
Recommendation 2.1SSAs (octreotide or l...
...ation 2.2In the less common circumstance...
...Second- or Later...
...on 2.3Peptide receptor radionuclide th...
...2.4Everolimus is recommended for pati...
...III. Systemi...
...mmendation 3.1SSAs (octreotide or lan...
...mmendation 3.2Chemotherapy (e.g., cap...
...mendation 3.3Chemotherapy (e.g., CAPTEM), everol...
...Second- or Late...
...3.4PRRT for SSTR-positive tumors,...
...IV. Systemic Th...
...ommendation 4.1The range of systemic option...
...1. WHO Classification and Grading Criteria for W...
Figure 1. Systemic Therapy for Tumor Contro...
...at cancer clinical trials are vital to inform m...